Fibrodysplasia ossificans progressiva (FOP) is one of the rarest and most disabling genetic conditions known. The University of Oxford is one of the few places in the world where this disease is being researched, with support from donations.
News from SGC
GMEC is pleased to announce the signing of the first collaborative research projects to be launched under theGMEC/Pfizer Rare Diseases agreement which was announced in 2014.
A new Drug Discovery Institute in Oxford focusing on finding new medicines for Azheimer’s is being funded by Alzheimer’s Research UK. The SGC will play a major role in this Institute, providing our expertise in protein production, protein crystallography and medicinal chemistry.
TORONTO, ON (December 9, 2014) — Dr. Aled Edwards, co-founder and CEO of
$2 million grant from the Bill & Melinda Gates Foundation furthers existing research on malaria and TB
Toronto, ON --Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.
As part of the International Year of Crystallography, the NDM at the University of Oxford has produced a four part documentary explaining how the field of structural biology has developed over the past 100 years, Oxford’s involvement in that development, and where we go from here. In the fourth part of this documentary
SGC-CHDI patent-free partnership selected as an 'Innovator' presenter at 'Partnering for Cures' meeting in New York, November 16-18, 2014.
2014 is the International Year of Crystallography and to celebrate this event NDM has produced a series of short films.
‘Revolutionary Biology’: Revolutionary Biology shows how the field of structural biology has developed over the past 100 years, Oxford’s involvement in that development, and where we go from here.
SGC Toronto will hold a free workshop ‘EZH2 Inhibitors: Target Validation through Chemical Biology’, on February 9th, 2015 at the Princess Margaret Cancer Centre in Toronto, ON.